The positive result tees Reata up to file for FDA approval of the activator of Nrf2 and expand development to other neurodegenerative diseases. 

Next-gen cancer biotech Checkmate Pharmaceuticals has grabbed a new chief medical officer after a year of C-suite shuffles.

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

University of Pennsylvania scientists designed CAAR-T cells to only target the cells that express autoantibodies in autoimmune diseases.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.

As Covance changes up its leadership amid a change at the top of its parent company, one of its former execs has jumped ship to midsize rival CRO.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.